The EPS miss is a mechanical artifact of a small share base and one-time professional fees, not a business deterioration signal. The operational turnaround is real — record margins, 92% net loss reduction, and strong sequential growth in higher-margin contracted pharmacy services. Traders should watch for continued margin expansion and the conversion of the 11 new 340B contracts signed in H1 2026 into revenue in Q3/Q4. The pending Pensacola pharmacy acquisition and planned national medication fulfillment website launch are additional catalysts. The stock's low market cap ($18M) and high institutional bullishness (86% buy rating) suggest asymmetric upside if the company delivers on its profitability guidance.
Price Chart
Executive Summary
NextPlat reported Q2 2026 revenue of $11.9M, slightly above the $11.0M consensus, but EPS of -$0.42 missed the -$0.21 estimate by 100%. The headline miss is misleading as the company reduced its net loss by 92% YoY to $144K, achieved record gross margins of 40%, and highlighted strong sequential growth in higher-margin 340B contracted pharmacy services. The stock's reaction will likely focus on the operational turnaround narrative and the path to profitability, rather than the EPS miss.
Key Financial Metrics
Key Facts
- Q2 2026 revenue of $11.9M, up 21% sequentially from $9.9M in Q1 2026.
- GAAP EPS of -$0.42 missed consensus of -$0.21 by 100%.
- Net loss reduced 92% YoY to $144K from $1.8M in Q2 2025.
- Record gross margin of 40%, up from 22% in Q2 2025.
- Contracted pharmacy revenue grew 136% YoY to $2.2M.
- E-commerce revenue up 27% sequentially to $4.1M.
- Cash of $11.9M, working capital of $14.2M, no material unsecured debt.
- Excluding $0.5M in one-time professional fees, the company achieved profitability in Q2.
- Management expects sustainable positive operating income for the remainder of 2026.
Financial Impact
Revenue of $11.9M vs $11.0M consensus; GAAP EPS of -$0.42 vs -$0.21 consensus. Net loss of $144K vs $1.8M in prior year.
Risk Factors
- Revenue declined 10% YoY ($11.9M vs $13.2M) due to lower payer reimbursement rates and payer mix in pharmacy prescription revenue.
- EPS miss of 100% vs consensus could trigger short-term selling pressure.
- Operating expenses increased slightly YoY due to $0.5M in one-time professional fees.
- Dependence on converting new 340B contracts into revenue; onboarding delays could slow growth.
- Small market cap ($18M) and low liquidity could amplify volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302850329 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | Press Release | $9.00 $9.05 | ▲ +0.50% | ▲ +1.65% | $8.62 (−4.22%) |
Oct 6, 2026 21d ago | 8-K | $9.29 $9.12 | ▼ −1.88% | ▼ −0.90% | $8.62 (−7.21%) |
Oct 6, 2026 21d ago | Press Release | $9.27 $9.00 | ▼ −2.91% | ▼ −2.77% | $8.62 (−7.01%) |
Aug 13, 2026 10w ago | Press Release | $8.11 $8.57 | ▲ +5.67% | ▲ +7.64% | $8.62 (+6.29%) |
Aug 3, 2026 12w ago | Press Release | $6.10 $6.36 | ▲ +4.26% | ▲ +2.23% | $8.62 (+41.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers